BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.1700
+0.0014 (0.83%)
At close: Mar 23, 2026, 4:00 PM EDT
0.1720
+0.0020 (1.18%)
Pre-market: Mar 24, 2026, 7:26 AM EDT
BioAtla Revenue
In the year 2024, BioAtla had annual revenue of $11.00M.
Revenue (ttm)
$11.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
9.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 250.00K | -179.00K | -41.72% |
| Dec 31, 2020 | 429.00K | -4.77M | -91.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBCAB News
- 21 days ago - BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets - GlobeNewsWire
- 2 months ago - BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - GlobeNewsWire
- 4 months ago - BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewsWire
- 4 months ago - BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 4 months ago - BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - GlobeNewsWire
- 4 months ago - BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - GlobeNewsWire
- 5 months ago - BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society - GlobeNewsWire
- 5 months ago - BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 - GlobeNewsWire